Humane Genomics
Humane Genomics, based in New York, NY, specializes in developing cancer-killing viruses, focusing on pediatric liver cancer with promising early results.
Services
Humane Genomics focuses on revolutionizing cancer treatment through the development of precision-designed oncolytic viral therapies. The company utilizes synthetic biology and hard tech to engineer cancer-killing viruses, specifically targeting pediatric liver cancer (hepatoblastoma) as their first indication. Their state-of-the-art platform supports the expedited design and testing of these therapies, ensuring unparalleled safety, a maximized therapeutic window, systematic delivery, and cost-effective production.
Founders
Humane Genomics participated in Y Combinator's S21 batch, indicating that the company was either founded or in its early stages of development around 2021. Specific details about the founders are not provided, but their vision and innovation have driven the company's efforts in engineering highly targeted cancer therapies.
Products
The primary product under development at Humane Genomics is a platform to engineer cancer-killing viruses. This platform is capable of designing viruses with a highly lytic RNA virus engineered with '2 factor authentication' for selective infection and replication. The goal is to create therapeutic solutions like the one targeting pediatric liver cancer, with in vivo (mouse) data showing a 50% reduction in tumor volume. The therapies have an on-target to off-target kill ratio greater than 1000, emphasizing their precision and effectiveness.
History
Humane Genomics was launched in 2021 and quickly made strides in the healthcare and therapeutics industry. It gained support by participating in Y Combinator's S21 batch, which helped lay the groundwork for its innovative platform. With a small team of 5 based in New York, NY, USA, the company has formed a crucial partnership with Texas Children's Hospital to advance their research and development efforts. Humane Genomics focuses primarily on the United States of America and America/Canada regions.
Sector
Humane Genomics operates within the healthcare sector, specializing in the sub-industry of therapeutics. Their work is at the intersection of healthcare and synthetic biology, advancing the frontiers of cancer treatment. The company is at an early stage of development and focuses on creating cutting-edge oncolytic viral therapies targeted at pediatric liver cancer. The use of Vesicular Stomatitis Virus (VSV) for its linear genome, ease of retargeting, highly lytic nature, extensive research, and low seroprevalence is a key element of their innovation.
